# EDGAR Filing Document

**Accession Number:** 0001433607
**File Stem:** 0001493152-25-024066
**Filing Date:** 2025-11
**Character Count:** 23691
**Document Hash:** da2b9f0693a0c42f74d478bc540b1721
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001493152-25-024066.hdr.sgml**: 20251118

**ACCESSION NUMBER**: 0001493152-25-024066

**CONFORMED SUBMISSION TYPE**: S-8

**PUBLIC DOCUMENT COUNT**: 16

**FILED AS OF DATE**: 20251118

**DATE AS OF CHANGE**: 20251118

**EFFECTIVENESS DATE**: 20251118

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** InspireMD, Inc.
- **CENTRAL INDEX KEY:** 0001433607
- **STANDARD INDUSTRIAL CLASSIFICATION:** SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 262123838
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** S-8
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 333-291617
- **FILM NUMBER:** 251494847

**BUSINESS ADDRESS:**
- **STREET 1:** 6303 WATERFORD DISTRICT DRIVE
- **STREET 2:** SUITE 215
- **CITY:** MIAMI
- **STATE:** FL
- **ZIP:** 33126
- **BUSINESS PHONE:** (888) 776-6804

**MAIL ADDRESS:**
- **STREET 1:** 6303 WATERFORD DISTRICT DRIVE
- **STREET 2:** SUITE 215
- **CITY:** MIAMI
- **STATE:** FL
- **ZIP:** 33126

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Saguaro Resources, Inc.
- **DATE OF NAME CHANGE:** 20080428

**As filed with the Securities and Exchange Commission on November 18, 2025**

Registration No. 333-

**United States**

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, D.C. 20549**

**FORM S-8**

**REGISTRATION STATEMENT**

**UNDER**

**THE SECURITIES ACT OF 1933**

**INSPIREMD, INC.**

(Exact name of registrant as specified in its charter)

---

| | |
|:---|:---|
| **Delaware** | **26-2123838** |
| (State or other jurisdiction of<br> incorporation or organization) | (I.R.S. Employer<br> Identification No.) |

---

**6303 Waterford District Drive**

**Suite 215**

**Miami, Florida 33126**

(Address of Principal Executive Offices)

**InspireMD, Inc. 2021 Equity Compensation Plan**

(Full title of the plan)

**Marvin Slosman**

**President and Chief Executive Officer**

**InspireMD, Inc.**

**6303 Waterford District Drive**

**Suite 215**

**Miami, Florida 33126**

**(888) 776-6804**

(Name, Address and Telephone Number of Agent For Service)

Copies to:

**Raffael M. Fiumara, Esq.**

**Gary Emmanuel, Esq.**

**Sami B. Ghneim, Esq.**

**Greenberg Traurig, P.A.**

**333 S.E. 2nd Avenue, Suite 4400**

**Miami, Florida 33131**

**Tel: (305) 579-0500**

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act

Large accelerated filer ☐ Accelerated filer ☐ Non-accelerated filer ☒ Smaller reporting company ☒ Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

**EXPLANATORY NOTE** 

**InspireMD, Inc. 2021 Equity Compensation Plan**

The purpose of this Registration Statement on Form S-8 (this "Registration Statement") is for InspireMD, Inc. (the "Company") to register an additional 4,723,370 shares of common Stock, par value $0.0001 per share, for issuance under the Company's 2021 Equity Compensation Plan (the "Plan"). In accordance with General Instruction E of Form S-8, the contents of the Company's Registration Statements on Form S-8 (File Nos. [333-260216](https://www.sec.gov/Archives/edgar/data/1433607/000149315221025307/forms-8.htm) and [333-272003](https://www.sec.gov/Archives/edgar/data/1433607/000149315223017934/forms-8.htm)), filed with the Securities and Exchange Commission (the "Commission") on October 13, 2021 and May 17, 2023, respectively, are incorporated herein by reference and the information required by Part II is omitted, except as supplemented by the information set forth below.

**PART I**

**INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS**

**Item 1. Plan Information.\***

**Item 2. Registrant Information and Employee Plan Annual Information. \***

\* The documents containing the information specified in this Part I of Form S-8 (plan information and Registrant information and employee plan annual information) will be sent or given to employees as specified by the Commission pursuant to Rule 428(b)(1) of the Securities Act. Such documents are not required to be and are not filed with the Commission either as part of this Registration Statement or as prospectuses or prospectus supplements pursuant to Rule 424. These documents and the documents incorporated by reference in this Registration Statement pursuant to Item 3 of Part II hereof, taken together, constitute a prospectus that meets the requirements of Section 10(a) of the Securities Act.

**PART II**

**INFORMATION REQUIRED IN THE REGISTRATION STATEMENT**

**Item 3. Incorporation of Documents by Reference.**

The following documents, which have been filed by the Company with the Commission are incorporated by reference in and made a part of this registration statement, as of their respective dates:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) the
 Company's Annual Report on [Form 10-K](https://www.sec.gov/Archives/edgar/data/1433607/000149315225009909/form10-k.htm) for the year ended December 31, 2024, filed with the Commission on March 12, 2025;

(b) the
 Company's Quarterly Reports on Form 10-Q for the quarters ended March 31, 2025, June 30, 2025 and September 30, 2025, filed
 with the Commission on [May 8, 2025](https://www.sec.gov/Archives/edgar/data/1433607/000164117225009250/form10-q.htm) , [August 4, 2025](https://www.sec.gov/Archives/edgar/data/1433607/000164117225022040/form10-q.htm) and [November 10, 2025](https://www.sec.gov/Archives/edgar/data/1433607/000149315225021503/form10-q.htm) , respectively;

(c) the
 Company's Definitive Proxy Statement on [Schedule 14A](https://www.sec.gov/Archives/edgar/data/1433607/000164117225004800/formdef14a.htm) filed on April 15, 2025, to the extent specifically incorporated by reference
 into Part III of the Annual Report on [Form 10-K](https://www.sec.gov/Archives/edgar/data/1433607/000149315225009909/form10-k.htm) for the fiscal year ended December 31, 2024, filed with the Commission on March 12,
 2025;

(c) the
 Current Reports on Form 8-K (other than the information furnished pursuant to Item 2.02 or 7.01 thereof or related exhibits furnished
 pursuant to Item 9.01 thereof) filed with the SEC on [March 12, 2025](https://www.sec.gov/Archives/edgar/data/1433607/000149315225009936/form8-k.htm) , [May 9, 2025](https://www.sec.gov/Archives/edgar/data/1433607/000164117225009364/form8-k.htm) , [June 3, 2025](https://www.sec.gov/Archives/edgar/data/1433607/000164117225013427/form8-k.htm) , [June 3, 2025](https://www.sec.gov/Archives/edgar/data/1433607/000164117225013433/form8-k.htm) , [June 13, 2025](https://www.sec.gov/Archives/edgar/data/1433607/000164117225014986/form8-k.htm) , [June 24, 2025](https://www.sec.gov/Archives/edgar/data/1433607/000164117225016293/form8-k.htm) , [July 9, 2025](https://www.sec.gov/Archives/edgar/data/1433607/000164117225018302/form8-k.htm) , [July 31, 2025](https://www.sec.gov/Archives/edgar/data/1433607/000164117225021675/form8-k.htm) , [August 5, 2025](https://www.sec.gov/Archives/edgar/data/1433607/000164117225022159/form8-k.htm) , [September 8, 2025](https://www.sec.gov/Archives/edgar/data/1433607/000149315225012805/form8-ka.htm) , [September 17, 2025](https://www.sec.gov/Archives/edgar/data/1433607/000149315225013828/form8-k.htm) and [November 4, 2025](https://www.sec.gov/Archives/edgar/data/1433607/000149315225020718/form8-k.htm) ; and

(d) the
 description of the Company's Common Stock in [Exhibit 4.1](https://www.sec.gov/Archives/edgar/data/1433607/000149315224008850/ex4-1.htm) to the Annual Report on Form 10-K for the fiscal year ended December
 31, 2024, filed with the SEC on March 12, 2025, and as may be further updated or amended in any amendment or report filed for such
 purpose.

All documents subsequently filed by us with the Commission pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Securities Exchange Act of 1934, as amended, prior to the filing of a post-effective amendment which indicates that all securities offered have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference in this registration statement and to be part hereof from the date of filing of such documents.

Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this registration statement to the extent that a statement herein, or in any subsequently filed document which also is or is deemed to be incorporated by reference, modifies or supersedes such statement. Any statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this registration statement.

**Item 8. Exhibits.**

A list of exhibits filed with this Registration Statement on Form S-8 is set forth on the Exhibit Index and is incorporated herein by reference.

**SIGNATURES**

Pursuant to the requirements of the Securities Act of 1933, the Company certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement on Form S-8 to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Miami, Florida, United States, on the 18th day of November, 2025.

---

| | |
|:---|:---|
| **INSPIREMD, INC.** | **INSPIREMD, INC.** |
| By: | */s/ Marvin Slosman* |
| Name: | Marvin Slosman |
| Title: | Chief Executive Officer |

---

**power of attorney and signatures**

We, the undersigned officers and directors of InspireMD, Inc., hereby severally constitute and appoint Marvin Slosman and Michael Lawless, and each of them individually, our true and lawful attorney to sign for us and in our names in the capacities indicated below any and all amendments or supplements, including any post-effective amendments, to this registration statement on Form S-8 and to file the same, with exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorney full power and authority to do and perform each and every act and thing requisite or necessary to be done in and about the premises, as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming our signatures to said amendments to this registration statement signed by our said attorney and all else that said attorney may lawfully do and cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Act, this registration statement on Form S-8 has been signed below by the following persons in the capacities and on the dates indicated.

---

| | | |
|:---|:---|:---|
| **Person** | **Capacity** | **Date** |
| */s/ Marvin Slosman* | Chief Executive Officer | November 18, 2025 |
| Marvin Slosman | (Principal Executive Officer), President, Director |  |
| */s/ Michael Lawless* | Chief Financial Officer, | November 18, 2025 |
| Michael Lawless | Principal Financial and Accounting Officer) |  |
| */s/ Paul Stuka* | Chairman of the Board of Directors | November 18, 2025 |
| Paul Stuka |  |  |
| */s/ Kathryn Arnold* | Director | November 18, 2025 |
| Kathryn Arnold |  |  |
| */s/ Michael Berman* | Director | November 18, 2025 |
| Michael Berman |  |  |
| */s/ Raymond Cohen* | Director | November 18, 2025 |
| Raymond Cohen |  |  |
| */s/ Dan Dearen* | Director | November 18, 2025 |
| Dan Dearen |  |  |
| */s/ Gary Roubin, M.D.* | Director | November 18, 2025 |
| Gary Roubin, M.D. |  |  |
| */s/ Scott R. Ward* | Director | November 18, 2025 |
| Scott R. Ward |  |  |

---

**EXHIBIT INDEX**

---

| | |
|:---|:---|
| **Exhibit No.** | **Description** |
| 3.1 | [Amended and Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.1 to the Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 9, 2015)](https://www.sec.gov/Archives/edgar/data/1433607/000161577415003178/s102096_ex3-1.htm) |
| 3.2 | [Amended and Restated Bylaws (incorporated by reference to Exhibit 3.2 to Current Report on Form 8-K filed with the Securities and Exchange Commission on June 29, 2021)](https://www.sec.gov/Archives/edgar/data/1433607/000149315221015545/ex3-2.htm) |
| 3.3 | [Certificate of Amendment to Amended and Restated Certificate of Incorporation of InspireMD, Inc. (incorporated by reference to Exhibit 3.1 to the Current Report on Form 8-K filed on May 25, 2016)](https://www.sec.gov/Archives/edgar/data/1433607/000161577416005628/s103343_ex3-1.htm) |
| 3.4 | [Certificate of Amendment to Amended and Restated Certificate of Incorporation of InspireMD, Inc. (incorporated by reference to Exhibit 3.1 to the Current Report on Form 8-K filed on September 29, 2016)](https://www.sec.gov/Archives/edgar/data/1433607/000149315216013705/ex3-1.htm) |
| 3.5 | [Certificate of Designation of Preferences, Rights and Limitations of Series C Convertible Preferred Stock (incorporated by reference to Exhibit 3.1 to the Current Report on Form 8-K filed on March 15, 2017)](https://www.sec.gov/Archives/edgar/data/1433607/000149315217002455/ex3-1.htm) |
| 3.6 | [Certificate of Amendment to Certificate of Designation of Preferences, Rights and Limitation of Series C Convertible Preferred Stock (incorporated by reference to Exhibit 3.1 to the Current Report on Form 8-K filed on November 29, 2017)](https://www.sec.gov/Archives/edgar/data/1433607/000149315217013917/ex3-1.htm) |
| 3.7 | [Certificate of Amendment to Certificate of Designation of Preferences, Rights and Limitation of Series B Convertible Preferred Stock (incorporated by reference to Exhibit 3.1 to the Current Report on Form 8-K filed on December 12, 2017)](https://www.sec.gov/Archives/edgar/data/1433607/000149315217014515/ex3-1.htm) |
| 3.8 | [Certificate of Amendment to Amended and Restated Certificate of Incorporation of InspireMD, Inc. (incorporated by reference to Exhibit 3.1 to the Current Report on Form 8-K filed on February 7, 2018)](https://www.sec.gov/Archives/edgar/data/1433607/000149315218001617/ex3-1.htm) |
| 3.11 | [Certificate of Amendment to Amended and Restated Certificate of Incorporation of InspireMD, Inc., dated March 27, 2019 (incorporated by reference to Exhibit 3.1 to the Current Report on Form 8-K filed on March 28, 2019)](https://www.sec.gov/Archives/edgar/data/1433607/000149315219004101/ex3-1.htm) |
| 3.12 | [Certificate of Amendment to Amended and Restated Certificate of Incorporation of InspireMD, Inc., dated April 14, 2021 (incorporated by reference to Exhibit 3.17 to Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on May 10, 2021)](https://www.sec.gov/Archives/edgar/data/1433607/000149315221010881/ex3-17.htm) |
| 3.13 | [Certificate of Amendment to Amended and Restated Certificate of Incorporation of InspireMD, Inc., dated September 13, 2023 (incorporated by reference to Exhibit 3.1 to the Current Report on Form 8-K filed on September 13, 2023)](https://www.sec.gov/Archives/edgar/data/1433607/000149315223032486/ex3-1.htm) |
| 4.1 | [Form of Common Stock Certificate (incorporated by reference to Exhibit 4.1 to Amendment No. 3 to Registration Statement on Form S-1 filed with the Securities and Exchange Commission on March 5, 2013)](https://www.sec.gov/Archives/edgar/data/1433607/000114420413012900/v328423_ex4-1.htm) |
| 5.1\* | [Opinion of Greenberg Traurig, P.A.](ex5-1.htm) |
| 23.1\* | [Consent of Kesselman & Kesselman, Certified Public Accountants (Isr.), a member firm of PricewaterhouseCoopers International Limited, independent registered public accounting firm for the registrant](ex23-1.htm) |
| 23.2\* | [Consent of Greenberg Traurig, P.A. (included in Exhibit 5.1)](ex5-1.htm) |
| 24.1\* | [Power of Attorney (included in the signature page)](#ak_001) |
| 99.1 | [The Company's 2021 Equity Compensation Plan (incorporated by reference to Annex A to the Company's Proxy Statement on Schedule 14A filed with the Commission on August 12, 2021).](https://www.sec.gov/Archives/edgar/data/1433607/000149315221019508/formdef14a.htm) |
| 107\* | [Filing Fee Table](ex107.htm) |
| \* | Filed herewith. |

---

## Exhibit 5.1

**Exhibit 5.1**

![](ex5-1_001.jpg)

November 18, 2025

InspireMD, Inc.

4 Menorat Hamaor St.

Tel Aviv, Israel 6744832

Re: InspireMD, Inc. Registration Statement on Form S-8

Ladies and Gentlemen:

We are rendering this opinion in connection with the Registration Statement on Form S-8 (the "<u>Registration Statement</u>") to be filed with the Securities and Exchange Commission under the Securities Act of 1933, as amended, with respect to the registration of up to 4,723,370 shares (the "<u>Shares</u>") of common stock, par value $0.0001 per share (the "<u>Common Stock</u>"), issuable pursuant to the InspireMD, Inc. 2021 Equity Compensation Plan (the "<u>Plan</u>").

We have examined: (i) the Registration Statement; (ii) the Company's Amended and Restated Certificate of Incorporation, as amended to date; (iii) the Company's Amended and Restated By-Laws, as amended to date; (iv) the Plan, (v) certain resolutions of the Board of Directors of the Company related to the filing of the Registration Statement, the authorization and issuance of the Shares and related matters, and (vi) the corporate proceedings relating to the registration of the Shares pursuant to the Plan.

In addition to the examination outlined above, we have conferred with various officers of the Company and have ascertained or verified, to our satisfaction, such additional facts as we deemed necessary or appropriate for the purposes of this opinion. In our examination, we have assumed the authenticity of all documents submitted to us as originals, the conformity to the original documents of all documents submitted to us as copies, the genuineness of all signatures on documents reviewed by us and the legal capacity of natural persons.

We have also assumed that, at the time of the issuance of the Shares: (i) the Registration Statement and any amendments thereto (including post-effective amendments) will have become effective and will remain effective, (ii) no stop order of the Commission preventing or suspending the use of the prospectus described in the Registration Statement will have been issued, (iii) the prospectus described in the Registration Statement and any required prospectus supplement will have been delivered to the recipient of the Shares as required in accordance with applicable law, (iv) the resolutions of the Board of Directors of the Company and the compensation committee of the Board of Directors of the Company referred to above will not have been modified or rescinded, (v) the Company will receive consideration for the issuance of the Shares required by the Plan and that is at least equal to the par value of the Common Stock, (vi) all requirements of the Delaware General Corporation Law, the Amended and Restated Certificate of Incorporation, as amended to date, and the Amended and Restated By-Laws, as amended to date, will be complied with when the Shares are issued, (vii) sufficient shares of Common Stock will be authorized for issuance under the Amended and Restated Certificate of Incorporation of the Company, as amended to date, that have not otherwise been issued or reserved for issuance and (viii) neither the issuance nor sale of the Shares will result in a violation of any agreement or instrument then binding upon the Company or any order of any court or governmental body having jurisdiction over the Company.

Based on the foregoing, we are of the opinion that the Shares that constitute original issuance shares will be validly issued, fully paid and nonassessable by the Company when the issuance of such Shares has been duly and validly approved by the board of directors of the Company and such Shares have been delivered in accordance with the Plan.

We do not express any opinion herein concerning any law other than the Delaware General Corporation Law, as currently in effect.

We consent to the filing of this opinion as an exhibit to the Registration Statement and we consent to the use of our name wherever it appears in the Registration Statement. In giving this consent, we do not hereby admit that we come within the category of persons whose consent is required under Section 7 of the Securities Act of 1933, as amended, or the rules and regulations of the Securities and Exchange Commission thereunder.

Very truly yours,

---

| |
|:---|
| */s/ Greenberg Traurig, P.A.* |
| Greenberg Traurig, P.A. |

---

## Exhibit 23.1

**Exhibit 23.1**

![](ex23-1_001.jpg)

**CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM**

We hereby consent to the incorporation by reference in this Registration Statement on Form S-8 of InspireMD Inc. of our report dated March 12, 2025 relating to the financial statements, which appears in InspireMD Inc.'s Annual Report on Form 10-K for the year ended December 31, 2024.

---

| | |
|:---|:---|
| Tel-Aviv, Israel | */s/ Kesselman & Kesselman* |
| November 18, 2025 | Certified Public Accountants (lsr.) |
|  | A member firm of PricewaterhouseCoopers International Limited |

---

Kesselman & Kesselman, 146 Derech Menachem Begin, Tel-Aviv 6492103, Israel,

*P.O Box 7187 Tel-Aviv 6107120, Telephone: +972 -3- 7954555, Fax:+972 -3- 7954556, www.pwc.com/il*

## Ex-Filing

?xml version='1.0' encoding='ASCII'?

**Exhibit 107**

**Calculation of Filing Fee Table**

Form S-8

(Form Type)

InspireMD, Inc.

(Exact Name of Registrant as Specified in its Charter)

Table 1: Newly Registered Securities

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
| **Security<br> Type** | **Security<br> Class Title** | **Fee<br> Calculation<br> Rule** | **Amount<br> Registered(1)** | **Proposed<br> Maximum**<br> **Offering<br> Price Per Share** | **Maximum<br> Aggregate**<br> **Offering Price** | **Fee Rate** | **Amount of<br> Registration<br> Fee** |
| Equity | Shares of common Stock, par value $0.0001 per share, reserved for issuance pursuant to the InspireMD, Inc. 2021 Equity Compensation Plan | 457(c); 457(h) | 4723370<sup>(1)</sup> | $1.73<sup>(2)</sup> | $8171430.10 | 0.0001381 | $1128.48 |
| **Total Offering Amount** | **Total Offering Amount** |  | 4723370 |  | $8171430.10 |  | $1128.48 |
| **Total Fees Previously Paid** | **Total Fees Previously Paid** |  |  |  |  |  |  |
| **Total Fee Offsets** | **Total Fee Offsets** |  |  |  |  |  |  |
| **Net Fee Due** | **Net Fee Due** |  |  |  |  |  | $1128.48 |

---

(1) Pursuant to Rule 416(a)
 under the Securities Act of 1933, as amended, this registration statement shall also cover any additional shares of common stock
 that become issuable under the InspireMD, Inc. 2021 Equity Compensation Plan by reason of any stock dividend, stock split, recapitalization
 or other similar transaction.

(2) The proposed maximum offering
 price per share is calculated in accordance with Rules 457(c) and 457(h) under the Securities Act, solely for purposes of calculating
 the registration fee on the basis of $1.73 per share, the average of the high and low price of the Registrant's ordinary shares
 as reported on the Nasdaq Capital Market on November 12, 2025.